HUBILO
2.2.2021 16:20:05 CET | Business Wire | Press release
Event technology company Hubilo has updated its virtual event platform to include support for all the European languages, to meet the demands of a growing global market for virtual events which is expected to be worth over $400bn by 2027.
Hubilo’s platform offers customers a DIY (Do It Yourself) feature that allows them to create events based on individual specifications using a few basic steps, including customizing events in their chosen language to make the entire process simple to understand and operate. The new multilingual feature enables Hubilo to support customers across Europe better, creating a truly universal hub.
Additional Features include a networking lounge where attendees can connect and video chat with the ones with similar interests, virtual booths that provide businesses and promoters with a separate online space to market their products, speaker lounges where attendees can see a list of all event speakers and their sessions and register and add sessions to their event itinerary, live and on-demand sessions, surveys and polls , gamification experiences , automated registrations and ticket processes, and 24/7 customer care services.
For the organizers, there is a provision of features like analytics and insights to help them with quality lead assessments for conversions, a system of records that acts as a reference point to ensure that the organizers have a complete understanding of the attendee engagement rate and interactions along with other required insights across various touchpoints at the event, a broadcast studio which eliminates the need of an additional video conference software, at the same time shares all the tools that are provided by the external software and branded themes , here you can customize your event as per your brand guideline to deliver the precise brand messaging.
Vaibhav Jain, Founder and CEO, Hubilo said: “We launched our virtual platform to deliver a richer online experience for organizers and attendees, mirroring numerous positive features of in-person events along with the addition of a few advanced ones. We are glad that we are able to offer a more inclusive range of languages to our existing, and new as well as prospective clients across Europe. In fact, in order to comply with the European rules and regulations, Hubilo will also now host information on European clients and attendees on dedicated EU servers, within the European jurisdiction.”
Hubilo, which lists Roche, GITEX and Informa Group among its customers, managed to pivot to deliver online virtual events in February 2020, backed by a $4.5m investment led by Lightspeed Venture Partners. Hubilo covers the entire spectrum of meetings, incentives, conferences, and exhibitions (MICE) for external and internal events such as trade fairs, job fairs, award shows, annual sales meet, employee engagement initiatives, town halls, office parties and more.
About Hubilo :
Event technology Company Hubilo has created a comprehensive virtual platform that meets all the event-based requirements through the integration of numerous technology tools. They have redefined the entire marketing landscape around virtual events to unlock massive value for key stakeholders, such as CMOs, event organizers, and sponsors. Hubilo covers the entire spectrum of meetings, incentives, conferences and exhibitions (MICE) which include FMCG, BFSI, Education, Healthcare and Pharmaceutical, Information Technology and Manufacturing, as well as several other industries. Founded in 2015 and pivoted in February 2020 by Vaibhav Jain and Mayank Agarwal, in just 5 years, Hubilo's clientele is inclusive of names like United Nations, Roche, Informa Markets, Tech in Asia, Fortune, AWS, Siemens, GITEX, to name a few.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210202005812/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ARIS Announced as Exclusive Process Intelligence Launch Partner for AWS European Sovereign Cloud8.6.2026 09:00:00 CEST | Press release
Partnership Will Enable Enterprises to Accelerate AI Adoption While Ensuring Digital Sovereignty ARIS, the process context foundation for enterprise AI deployment, today announced its collaboration with Amazon Web Services (AWS) to support organizations navigating increasingly complex digital sovereignty requirements while accelerating AI-driven transformation. Many European enterprises face growing pressure to ensure sensitive operational and business data remains under European governance and regulatory control. Through the AWS European Sovereign Cloud (ESC), they will be able to combine advanced cloud and AI capabilities with enhanced operational separation, EU-based governance, and strict data residency controls. ARIS will support customers looking to operationalize AI safely and at scale within these boundaries by providing the process intelligence, governance, and operational context required for trusted enterprise AI deployment. “AI is moving rapidly from experimentation to oper
Cosylab Launches PlanOne™ Treatment Planning System for Particle Therapy8.6.2026 08:00:00 CEST | Press release
Cosylab today announced the commercial launch of PlanOne™, a treatment planning system for particle therapy, bringing physics-accurate, radiobiologically informed planning and a unified clinical workflow into a single environment. PlanOne™ is FDA 510(k) cleared. "PlanOne™ began with listening. Over the years, our work on control systems in radiation oncology has put us in direct, ongoing contact with medical physicists and clinical teams at some of the leading facilities in the world," said Mark Pleško, CEO of Cosylab. "Our partners have been clear on what matters most for particle therapy: physics accuracy they can defend, clinical confidence at the point of plan approval, and a platform built to grow with AI and adaptive workflows. We designed PlanOne™ around those three priorities, and we'll keep developing it together with the clinical community that helped shape it." Physics-accurate, radiobiologically informed planning PlanOne™ is built on a GPU-accelerated Monte Carlo dose engin
BitGo MENA Launches Regulated Electronic Trading, Delivering Full Suite Trading Services to the Region8.6.2026 06:00:00 CEST | Press release
BitGo MENA FZE (“BitGo MENA”), a subsidiary of BitGo Holdings, Inc. (NYSE: BTGO) (“BitGo”), the digital asset infrastructure company, today announced the launch of electronic trading in the Middle East and North African (MENA). With this launch, clients can now access a comprehensive trading solution combining BitGo MENA’s established over-the-counter (OTC) trading offering with institutional-grade electronic execution, all operating under BitGo MENA’s Broker-Dealer license from Dubai’s Virtual Assets Regulatory Authority (VARA). The launch further expands BitGo MENA’s regulated product suite under VARA’s oversight, marking another step in the region’s continued buildout of institutional digital asset infrastructure amid growing demand for integrated execution and custody solutions. “The Middle East and North Africa has quickly become one of the most exciting regions in the world for digital assets, with regulators, institutions, and innovators moving with real purpose,” said Mike Bels
Vertex Presents New Data on ALYFTREK® at European Cystic Fibrosis Conference5.6.2026 18:00:00 CEST | Press release
- ALYFTREK Phase 3 data on children with cystic fibrosis ages 2 to 5 with vanzacaftor/tezacaftor/deutivacaftor-responsive genotypes including F/F and F/MF shows 65% reached sweat chloride levels of <30 mmol/L; Vertex on track to initiate global regulatory submissions in first half of 2026 - - Long-term 96-week interim analyses from two open-label extension studies demonstrate positive safety and efficacy profile of ALYFTREK in people with cystic fibrosis ages 6 and older -- Phase 3 data on TRIKAFTA® in children 1 to <2 years also presented; Vertex has initiated global regulatory submissions - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data demonstrating the potentially transformative impact of treating cystic fibrosis (CF) with ALYFTREK ® (vanzacaftor/tezacaftor/deutivacaftor) in children ages 2 to 5, as well as data from 96-week interim analyses of two open-label extension studies of ALYFTREK in children 6 to 11 years and people 12 years and older demonstrating
Owkin to Build AI Agents as Part of a Multi-Year K Pro Collaboration with Sanofi5.6.2026 13:00:00 CEST | Press release
Owkin, the agentic AI company pioneering Biological Artificial Superintelligence to transform drug discovery and development, today announced a multi-year collaboration with Sanofi to co-develop next-generation biopharma agents, to be backed by a five-year license for K Pro, Owkin’s AI Scientist. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260605704506/en/ K Pro, Owkin's AI scientist for biology, powered by multimodal patient data for smarter biopharma decision making. Owkin and Sanofi have collaborated since 2021 through a €90 million strategic partnership focused on target identification in oncology and patient subgrouping. The collaboration was later expanded to include drug positioning for Sanofi’s immunology pipeline. This new collaboration represents the next evolution in the partnership. During the five-year collaboration, Owkin will lead the end-to-end development of novel AI-driven biopharma agents purpose-built
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom